Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
07.05. | Genelux GAAP EPS of -$0.21 | 1 | Seeking Alpha | ||
06.05. | Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates | 67 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter... ► Artikel lesen | |
GENELUX Aktie jetzt für 0€ handeln | |||||
06.05. | GENELUX Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
08.04. | Benchmark maintains $25 target on Genelux stock, optimistic on trials | 1 | Investing.com | ||
31.03. | H.C. Wainwright maintains Buy on Genelux shares, target at $30 | 2 | Investing.com | ||
28.03. | Genelux GAAP EPS of -$0.95 misses by $0.07 | 1 | Seeking Alpha | ||
28.03. | GENELUX Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
28.03. | Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | 131 | GlobeNewswire (Europe) | - Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer - - Positive Preliminary Phase 1b/2... ► Artikel lesen | |
28.03. | GENELUX Corp - 10-K, Annual Report | 1 | SEC Filings | ||
26.03. | Benchmark maintains $25 target on Genelux following trial data | 1 | Investing.com | ||
25.03. | Genelux Prices 3 Mln Stock Offering At $3.50/shr, Stock Fell | 1 | RTTNews | ||
25.03. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
25.03. | Genelux prices 3M shares at $3.50 in underwritten public offering | 3 | Seeking Alpha | ||
25.03. | Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
25.03. | Genelux Corporation: Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer | 464 | GlobeNewswire (Europe) | - Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced... ► Artikel lesen | |
02.03. | Why Genelux Corporation (GNLX) is Skyrocketing So Far in 2025 | 2 | Insider Monkey | ||
03.02. | Genelux Appoints Matthew Pulisic As CFO, Stock Drops | - | RTTNews | ||
03.02. | Genelux names Matthew Pulisic as CFO | 2 | Seeking Alpha | ||
03.02. | Genelux ernennt neuen CFO | - | Investing.com Deutsch | ||
03.02. | Genelux Corporation Announces New Chief Financial Officer | 142 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
89BIO | 10,250 | +3,12 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
TREVI THERAPEUTICS | 7,060 | +4,75 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Patients saw a... ► Artikel lesen |